ACAA1抗体—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using ACAA1 mouse mAb against mouse liver (1)and mouse kidney (2) lysate.    

  
  

•  

   

     Flow cytometric analysis of HL-60 cells using ACAA1 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human ovarian cancer tissues using ACAA1 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human rectum cancer tissues using ACAA1 mouse mAb with DAB staining.    

  
  

The ACAA1 antibody targets acetyl-CoA acyltransferase 1 (ACAA1), a key enzyme in the peroxisomal β-oxidation pathway. ACAA1. also known as peroxisomal thiolase 1. catalyzes the final step of fatty acid degradation, cleaving 3-ketoacyl-CoA into acetyl-CoA and a shortened acyl-CoA molecule. This enzyme is critical for metabolizing very-long-chain fatty acids (VLCFAs), branched-chain fatty acids, and bile acid intermediates. Dysregulation of ACAA1 is linked to peroxisomal disorders, such as Zellweger spectrum disorders, and metabolic conditions like insulin resistance or neurodegenerative diseases.

ACAA1 antibodies are essential tools for studying peroxisomal function, lipid metabolism, and associated pathologies. They enable detection and quantification of ACAA1 protein levels in tissues or cell lines via techniques like Western blotting, immunohistochemistry, and immunofluorescence. Researchers use these antibodies to explore ACAA1's role in cellular energy homeostasis, its interaction with other β-oxidation enzymes, and its potential as a biomarker in metabolic or cancer studies. Recent studies also investigate ACAA1's involvement in oxidative stress responses and inflammation. Commercial ACAA1 antibodies are typically raised in rabbits or mice, with validation in knockout models to ensure specificity. Understanding ACAA1 dynamics through such tools advances insights into metabolic diseases and therapeutic targeting.